Citigroup’s Valion Bio VBIO Stock Holding History

Citigroup’s Portfolio VBIO Stock Details VBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,998	Closed	-$7.25K	–	6397
2025 Q4	$7.25K	Buy	4,998 +3,568	+250%	+$8.14K	﹤0.01%	5147
2025 Q3	$4.13K	Buy	+1,430	New	+$4.93K	﹤0.01%	5285
2023 Q4	–	Sell	-41	Closed	-$1.22K	–	5864
2023 Q3	$1.22K	Buy	+41	New	+$3.03K	﹤0.01%	5064

Other funds holding VBIO

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Citigroup's VBIO Position: Q1 2026 in Review

Citigroup sold out of Valion Bio (VBIO) in Q1 2026, closing a stake of 4,998 shares — an estimated $7.25K sold.

Citigroup first reported a position in VBIO in Q3 2023 and held it in 3 quarters. The position peaked at $7.25K in Q4 2025. 9 funds tracked by Wall St. Rank hold VBIO as of Q1 2026.

Citigroup reported no remaining Valion Bio position as of Q1 2026 after selling out during the quarter.
Citigroup sold 4,998 Valion Bio shares in Q1 2026, an estimated $7.25K.
Citigroup first reported a position in Valion Bio in Q3 2023 and held it in 3 quarters.
Citigroup's Valion Bio position peaked at $7.25K in Q4 2025.
9 funds tracked by Wall St. Rank held Valion Bio as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.